Skip to content
Open in App
UCB logo

UCB

web2

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology...

Symbol · UCB
Company profile

About

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company offers Cimzia for ankylosing spondylitis (AS), axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, polyarticular juvenile idiopathic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; and Neupro for Parkinson’s disease and restless legs syndrome. It also provides Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. In addition, the company offers Evenity for the treatment of osteoporosis in postmenopausal women; Bimzelx to treat plaque psoriasis, psoriatic arthritis, hidradenitis suppurativa, and axial spondyloarthritis; Fintepla for the treatment of Dravet and Lennox-Gastaut syndrome; and RYSTIGGO and ZILBRYSQ to treat people living with generalized myasthenia gravis. Further, it develops KYGEVVI (doxecitine/doxribtimine) for thymidine kinase 2 deficiency disorder; fenfluramine to treat CDKL5 deficiency disorder, and RETT-Syndrome; dapirolizumab pegol for systemic lupus erythematosus; STACCATO alprazolam for treating stereotypical prolonged seizures; bepranemab to treat Alzheimer’s disease; and UCB9741 for atopic dermatitis, non cystic fibrosis bronchiectasis, and chronic obstructive pulmonary disease. Additionally, it engages in the contract manufacturing activities. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.

Explore by sector

Explore this sector

Market identity

Exchange listings

Listing identities only. Orbitrum does not publish live prices or market performance on this public profile.

Progress

Roadmap

BE BOLD trial meets primary ACR50 endpoint versus SKYRIZI

KEY STEP

UCB announced on March 11, 2026 that BIMZELX demonstrated statistically significant superiority over SKYRIZI on the ACR50 primary efficacy endpoint at week 16 in the BE BOLD study of adults with active psoriatic arthritis. UCB also reported that treatment was generally well tolerated with no new safety signals observed through week 16.

Roadmap reference

UCB completes acquisition of Candid Therapeutics

KEY STEP

UCB completed its acquisition of Candid Therapeutics on June 17, 2026. The transaction is valued at up to US $2.2 billion, consisting of US $2 billion in upfront payments and up to US $200 million in potential future milestone payments. The acquisition adds cizutamig and Candid’s broader T cell engager capabilities to UCB’s immunology pipeline.

Roadmap reference

UCB reaches U.S. government drug pricing and tariff agreement

KEY STEP

UCB announced on August 31, 2026 that it reached an agreement with the U.S. government covering medicine pricing and domestic manufacturing. UCB committed to a more balanced pricing approach for future medicine launches, participation in the Government’s GENEROUS program and continued U.S. manufacturing investment. UCB stated that, as a result of the agreement, it will not be subject to Section 232 pharmaceutical tariffs on current products or future pricing mandates. Specific commercial terms remain confidential.

Roadmap reference
People

Company team

JM

Jonathan M. Peacock

Independent Chair of the Board

Company leadership profile.

JT

Jean-Christophe Tellier

CEO & Executive Director

Company leadership profile.

CJ

Charles-Antoine Janssen

Vice-Chair of the Board

Company leadership profile.

ME

Mark Eyskens

Honorary Chairman

Company leadership profile.

GJ

Georges Jacobs de Hagen

Honorary Chairman

Company leadership profile.

Dd

Diégo du Monceau de Bergendal

Honorary Chairman

Company leadership profile.

KB

Karel Boone

Honorary Chairman

Company leadership profile.

GN

Gerhard N. Mayr

Honorary Chairman

Company leadership profile.

DJ

Daniel Janssen

Honorary Deputy Chairman

Company leadership profile.

NG

Nefertiti Greene

Independent Director

Company leadership profile.

JL

Judy L. Gawlik Brown

Independent Director

Company leadership profile.

JC

Jonkheer Cedric van Rijckevorsel

Director

Company leadership profile.

CJ

Cyril Janssen

Director

Company leadership profile.

UA

Ulf Arne Wiinberg

Independent Director

Company leadership profile.

PL

Pierre L. Gurdjian

Independent Director

Company leadership profile.

JB

Jan Berger

Independent Director

Company leadership profile.

MC

Maelys Castella

Independent Director

Company leadership profile.

DT

Dolca Thomas

Independent Director

Company leadership profile.

FP

Fiona Powrie

Independent Director

Company leadership profile.

SH

Stef Heylen

Representative Director

Company leadership profile.

JV

Jean-Louis Vanherweghem

Honorary Director

Company leadership profile.

GK

Guy Keutgen

Honorary Director

Company leadership profile.

AJ

Alan John Blinken

Honorary Director

Company leadership profile.

PL

Prince Lorenz

Honorary Director

Company leadership profile.

FR

Frederic Roch Doliveux

Honorary Director

Company leadership profile.

PJ

Peter J. Fellner

Honorary Director

Company leadership profile.

Gv

Gaëtan van de Werve

Honorary Director

Company leadership profile.

Ad

Arnoud de Pret Roose de Calesberg

Honorary Director

Company leadership profile.

NJ

Norman J. Ornstein

Honorary Director

Company leadership profile.

JK

Jean-Pierre Kinet

Honorary Director

Company leadership profile.

Jv

Jean van Rijckevorsel

Honorary Director

Company leadership profile.

TF

Thomas Fulton Wilson McKillop

Honorary Director

Company leadership profile.

AD

Albrecht De Graeve

Honorary Director

Company leadership profile.

AD

Alice Dautry

Honorary Director

Company leadership profile.

KE

Kay Elizabeth Davies

Honorary Director

Company leadership profile.

Expert coverage

1 expert evaluated UCB.

Orbitrum research

Experts evaluating UCB

Explore the public profiles of experts who have evaluated this project.

Orbitrum Academy

Learn how to read a project assessment